Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib + Trastuzumab + Vinorelbine in Trastuzumab-refractory HER2+ Breast Cancer
NCT03947242Unknown
- Sponsor
- Henan Cancer Hospital
- Start
- Jun 2019
- Primary completion
- Jun 2020
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
01
Overview
Open-label, single-arm trial of pyrotinib in breast cancer, sponsored by Henan Cancer Hospital. Primary endpoint: Objective Response Rate at 12 months. Status: unknown.
02
Drugs
pyrotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03947242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03947242.